Skip to main content

Table 1 Molecular Summary of in vivo drug efficacy trials carried out by the participant countries

From: Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites

Country Drugs studied in efficacy trials in vivo Follow-up period (days) Age range of study participants
Burkina Faso Dihydroartemisinin + piperaquine 42 6 months - 53 years
  Artemether + lumefantrine 28/42 6 months - 39 years
  Amodiaquine 28 6 months - 18 years
  Amodiaquine + artesunate 28 6 months - 30 years
  Amodiaquine + sulphadoxine-pyrimethamine 42 6 months - 55 years
Cameroon (Yaoundé) Sulphadoxine-pyrimethamine 28 5 - 59 months
  Amodiaquine   
  Amodiaquine + sulphadoxine pyrimethamine   
Cameroon (Buea) Artesunate + sulphadoxine-pyrimethamine 28 6 - 60 months
  Amodiaquine + artesunate   
Kenya Chloroquine 14 5 months-18 years
  Sulphadoxine-pyrimethamine 28  
  Sulphadoxine pyrimethamine + Cotrimoxazole   
Mali Chloroquine 14 6 - 60 months
  Amodiaquine 28  
  Sulphadoxine-pyrimethamine   
Sudan Chloroquine 28 6 months - 7 years
  Sulphadoxine-pyrimethamine   
  Artesunate + sulphadoxine-pyrimethamine